Research Studies

At CPMG, we dedicate our efforts to improve disease prevention, diagnosis, and treatment. Our researchers and physicians lead many research studies with the goal to implement personalized medicine in clinical practice and to bring genetic medicine into standard care.

Participating in research studies not only gives a patient the opportunity of being evaluated by some of the most talented physicians in the country, but also helps to make a difference for other patients for generations to come. Every action our patients take in research studies matters and is appreciated.

Below are available research studies with corresponding contacts. Email us with any questions at cpmg_info@cumc.columbia.edu.

Cure Glomerulonephropathy Network

Join a team of medical research professionals to study the following glomerular diseases: Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy (MN), and IgA Nephropathy (IgAN and IgAV).

Exome Sequencing for Solid Organ Transplantation

A major opportunity for implementation of genomic medicine is in the area of transplantation. Patients with a solid organ transplantation are enriched for genetic disorders, and also experience a distinct set of complications, such as cardiovascular disease, cancer or thrombotic events that may have a genetic underpinning. However, the utility of genetic analysis for the diagnosis and management of patients with solid organ transplants has not been systematically investigated. Our overarching goals are to introduce the use of exome sequencing for making a precise diagnosis of organ failure in transplant patients and also the use of genomic information beyond diagnostic variants for clinical care management. This project is funded by Natera.

Past Studies

All of Us

The All of Us Research Program is a momentous effort to advance individualized prevention, treatment, and care for people of all backgrounds. The overall aim is to enroll 1 million or more volunteers and oversample communities that have been underrepresented in research to make the program the largest, most diverse resource of its kind.

RenaCARE

Chronic kidney disease (CKD) affects more than 10% of the global population, and approximately 25% of those patients have a family history of kidney disease. Exome sequencing yields a genetic diagnosis in 9.3% of cases. Natera offers Renasight™, a next generation sequencing (NGS) multi-gene mutation assay, which may be used to confirm or reclassify a clinical diagnosis, identify target therapies, and provide insights for genetic counseling, family planning and clinical trial access. The purpose of this study is to assess the clinical utility of Renasight in patients with CKD.